

Colgate Palmolive

Healthy recovery, innovation to drive growth

Colgate reported a healthy 3QFY21 with 8% YoY net revenue growth (HSIE 7%) and 10% domestic business growth. Toothpaste saw 10% growth with volume growth of 5%. Market share was maintained (slightly up) despite rising competition. Toothbrush saw recovery, posting low single digit growth. Personal care growth remained robust, led by new launches and accelerating demand. The company saw strong performance across channels, especially in MT and e-comm. GM expansion was healthy, aided by price hike and product mix. Entry into new categories and expansion of existing brands will continue to drive growth for Colgate. Revenue contribution from new launches should increase in the coming years (as of now 2-3%) as most of the new launches are scalable and not seeing cannibalisation. We slightly increase our EPS estimates for FY22/FY23. We value Colgate at 42x P/E on Mar-23E EPS and derive a target price of Rs 1,772. Maintain ADD.

- YoY (+4% in 3QFY20 and +5% in 2QFY21), slightly ahead of our expectation of 7% YoY growth. Domestic net sales grew by 10% YoY. Toothbrush saw low single digit growth, but it was compensated by higher growth in personal care. Toothpaste grew at 10% YoY, with 5% volume growth. The company continued its aggression within new launches with the launch of Colgate Magik- a first-of-its-kind augmented reality toothbrush for kids. During 9MFY21, Colgate Vedshakti franchise was broadened into mouth spray and oil pulling. The company also made several other new launches and relaunches in toothpaste and toothbrush during this period.
- Strong margin expansion: Gross margin was healthy with an expansion of 403bps YoY to 69.8% (+60bps in 3QFY20 and +339bps in 2QFY21), beating our estimate of 147bps YoY expansion. Employee/A&P expenses grew by 13/38% YoY while other expenses declined by 6% YoY. EBITDA margin expanded by 253bps YoY to 30.1% (-105bps in 3QFY20 and +541bps in 2QFY21), ahead of our expectation of 167bps YoY expansion. EBITDA grew by 17% YoY (HSIE 13%). PBT grew by 24% YoY while PAT grew by 25% YoY.
- Management call takeaways: (1) Sustained commodity inflation can lead to price hikes in FY22; (2) the company does not believe it has lost any market share; (3) new launches have a revenue mix of ~3%; (4) e-comm revenue mix stands at ~2.5% with potential to reach ~5-6%; (5) A&P is expected to remain slightly more than 13% of revenue.

Quarterly/Annual Financial summary

		101 (70)	2QFY21	QoQ (%)	FY20	FY21E	FY22E	FY23E
12,319	11,472	7.4	12,855	(4.2)	45,251	48,183	52,567	56,750
3,706	3,161	17.3	4,093	(9.5)	12,017	14,415	15,456	16,812
2,484	1,991	24.7	2,742	(9.4)	8,165	9,621	10,397	11,487
9.1	7.3	24.7	10.1	(9.4)	30.0	35.3	38.2	42.2
					52.1	44.2	40.9	37.0
					35.0	29.1	26.8	24.4
					64.9	76.8	89.1	98.8
	3,706 2,484 9.1	3,706 3,161 2,484 1,991	3,706 3,161 17.3 2,484 1,991 24.7 9.1 7.3 24.7	3,706 3,161 17.3 4,093 2,484 1,991 24.7 2,742 9.1 7.3 24.7 10.1	3,706 3,161 17.3 4,093 (9.5) 2,484 1,991 24.7 2,742 (9.4) 9.1 7.3 24.7 10.1 (9.4)	3,706 3,161 17.3 4,093 (9.5) 12,017 2,484 1,991 24.7 2,742 (9.4) 8,165 9.1 7.3 24.7 10.1 (9.4) 30.0 52.1 35.0 64.9	3,706 3,161 17.3 4,093 (9.5) 12,017 14,415 2,484 1,991 24.7 2,742 (9.4) 8,165 9,621 9.1 7.3 24.7 10.1 (9.4) 30.0 35.3 52.1 44.2 35.0 29.1 64.9 76.8	3,706 3,161 17.3 4,093 (9.5) 12,017 14,415 15,456 2,484 1,991 24.7 2,742 (9.4) 8,165 9,621 10,397 9.1 7.3 24.7 10.1 (9.4) 30.0 35.3 38.2 52.1 44.2 40.9 35.0 29.1 26.8 64.9 76.8 89.1

Source: Company, HSIE Research

ADD

CMP (as on 28	Rs 1,563	
Target Price		Rs 1,772
NIFTY		13,818
KEY CHANGES	OLD	NEW
Rating	ADD	ADD
Price Target	Rs 1,723	Rs 1,772
EPS %	FY22E	FY23E
EF3 %	3%	3%
<u> </u>	•	•

KEY STOCK DATA

Bloomberg code	CLGT IN
No. of Shares (mn)	272
MCap (Rs bn) / (\$ mn)	425/5,824
6m avg traded value (Rs mn)	1,169
52 Week high / low R	s 1,676/1,065

STOCK PERFORMANCE (%)

	3 M	6 M	12M
Absolute (%)	1.5	12.4	5.5
Relative (%)	(15.9)	(9.4)	(8.9)

SHAREHOLDING PATTERN (%)

	Sep-20	Dec-20
Promoters	51.00	51.00
FIs & Local MFs	10.82	10.11
FPIs	15.67	16.59
Public & Others	22.51	22.30
Pledged Shares	0.00	0.00
Source : BSE		

Pledged shares as % of total shares

Varun Lohchab

varun.lohchab@hdfcsec.com +91-22-6171-7334

Naveen Trivedi

naveen.trivedi@hdfcsec.com +91-22-6171-7324

Aditya Sane

aditya.sane@hdfcsec.com +91-22-6171-7336



HSIE Results Daily



Disclosure:

Authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. **does not have** any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate **does not have** any material conflict of interest.

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3075 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

HDFC securities

Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171-7330 www.hdfcsec.com